FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783457746> ?p ?o ?g. }

• W2783457746 endingPage "539" @default.
• W2783457746 startingPage "528" @default.
• W2783457746 abstract "Advancements in molecular profiling and endocrine therapy (ET) have led to more focused clinical attention on precision medicine. These advances have expanded our understanding of breast cancer (BC) pathogenesis and hold promising implications for the future of therapy. The estrogen receptor-α is a predominant endocrine regulatory protein in the breast and in estrogen-induced BC. Successful targeting of proteins and genes within estrogen receptor (ER) nuclear and nonnuclear pathways remains a clinical goal. Several classes of antiestrogenic agents are available for patients with early, advanced, or metastatic BC, including selective ER modulators, aromatase inhibitors, and a selective ER degrader. Clinical development is focused upon characterizing the efficacy and tolerability of inhibitors that target the phosphatidylinositol 3 kinase (PI3K)/akt murine thymoma viral oncogene (AKT)/mammalian target of rapamycin inhibitor (mTOR) signaling pathway or the cyclin-dependent kinase 4/6 (CDK4/6) cell cycle pathway in women with hormone receptor-positive, human epidermal growth receptor 2-negative BC who have demonstrated disease recurrence or progression. De novo and acquired resistance remain a major challenge for women with BC receiving antiestrogenic therapy. Therefore, sequential combination of targeted ET is preferred in these patients, and the ever-increasing understanding of resistance mechanisms may better inform the selection of future therapy. This review describes the intricate roles of the PI3K/AKT/mTOR and CDK4/6 pathways in intracellular signaling and the use of endocrine and endocrine-based combination therapy in BC.The foundational strategy for treating hormone receptor-positive, human epidermal growth receptor 2-negative, advanced breast cancer includes the use of endocrine therapy either alone or in combination with targeted agents. The use of combination therapy aims to downregulate cell-signaling pathways with the intent of minimizing cellular crosstalk, which can otherwise result in continued tumorigenesis or progression through redundant pathways. This review provides the clinician with the molecular rationale and clinical evidence for these treatments and refers to evidence-based guidelines to inform the decision-making process." @default.
• W2783457746 created "2018-01-26" @default.
• W2783457746 creator A5044108002 @default.
• W2783457746 creator A5069795948 @default.
• W2783457746 date "2018-01-19" @default.
• W2783457746 modified "2023-10-18" @default.
• W2783457746 title "Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance" @default.
• W2783457746 cites W1565310327 @default.
• W2783457746 cites W1576570775 @default.
• W2783457746 cites W1761987988 @default.
• W2783457746 cites W1792508556 @default.
• W2783457746 cites W1913159188 @default.
• W2783457746 cites W1982223747 @default.
• W2783457746 cites W1991601194 @default.
• W2783457746 cites W1992477322 @default.
• W2783457746 cites W1995416038 @default.
• W2783457746 cites W1999065747 @default.
• W2783457746 cites W2012502745 @default.
• W2783457746 cites W2018803393 @default.
• W2783457746 cites W2020099088 @default.
• W2783457746 cites W2021145743 @default.
• W2783457746 cites W2026842712 @default.
• W2783457746 cites W2029754521 @default.
• W2783457746 cites W2030676208 @default.
• W2783457746 cites W2030678473 @default.
• W2783457746 cites W2031131661 @default.
• W2783457746 cites W2044702943 @default.
• W2783457746 cites W2052075818 @default.
• W2783457746 cites W2059454194 @default.
• W2783457746 cites W2061671852 @default.
• W2783457746 cites W2067342462 @default.
• W2783457746 cites W2068044367 @default.
• W2783457746 cites W2072958478 @default.
• W2783457746 cites W2073367400 @default.
• W2783457746 cites W2078502999 @default.
• W2783457746 cites W2095092592 @default.
• W2783457746 cites W2096283457 @default.
• W2783457746 cites W2101844536 @default.
• W2783457746 cites W2101982508 @default.
• W2783457746 cites W2107677500 @default.
• W2783457746 cites W2117357260 @default.
• W2783457746 cites W2117497402 @default.
• W2783457746 cites W2121155074 @default.
• W2783457746 cites W2132180344 @default.
• W2783457746 cites W2133958387 @default.
• W2783457746 cites W2137084288 @default.
• W2783457746 cites W2137177885 @default.
• W2783457746 cites W2138317169 @default.
• W2783457746 cites W2142334766 @default.
• W2783457746 cites W2143764959 @default.
• W2783457746 cites W2144790402 @default.
• W2783457746 cites W2152654745 @default.
• W2783457746 cites W2153255245 @default.
• W2783457746 cites W2154608911 @default.
• W2783457746 cites W2154626333 @default.
• W2783457746 cites W2154692501 @default.
• W2783457746 cites W2154871907 @default.
• W2783457746 cites W2156119355 @default.
• W2783457746 cites W2161551022 @default.
• W2783457746 cites W2164541907 @default.
• W2783457746 cites W2168106284 @default.
• W2783457746 cites W2169708904 @default.
• W2783457746 cites W2177855755 @default.
• W2783457746 cites W2255638054 @default.
• W2783457746 cites W2280154192 @default.
• W2783457746 cites W2290950904 @default.
• W2783457746 cites W2292399457 @default.
• W2783457746 cites W2295971206 @default.
• W2783457746 cites W2346465624 @default.
• W2783457746 cites W2374277491 @default.
• W2783457746 cites W2396213387 @default.
• W2783457746 cites W2404884142 @default.
• W2783457746 cites W2464812533 @default.
• W2783457746 cites W2475269618 @default.
• W2783457746 cites W2514365970 @default.
• W2783457746 cites W2514511766 @default.
• W2783457746 cites W2516966009 @default.
• W2783457746 cites W2528767298 @default.
• W2783457746 cites W2552099557 @default.
• W2783457746 cites W2557953210 @default.
• W2783457746 cites W2558360748 @default.
• W2783457746 cites W2560367415 @default.
• W2783457746 cites W2577185634 @default.
• W2783457746 cites W2592994249 @default.
• W2783457746 cites W2611953519 @default.
• W2783457746 cites W2613226689 @default.
• W2783457746 cites W2617437931 @default.
• W2783457746 cites W2619858681 @default.
• W2783457746 cites W2620993107 @default.
• W2783457746 cites W2621429580 @default.
• W2783457746 cites W2621727779 @default.
• W2783457746 cites W2621772424 @default.
• W2783457746 cites W2622133119 @default.
• W2783457746 cites W2622249265 @default.
• W2783457746 cites W2622877155 @default.
• W2783457746 cites W2624068231 @default.
• W2783457746 cites W2624659532 @default.
• W2783457746 cites W2743639018 @default.

• next